Heplisav-B: A Superior Hepatitis B Vaccine for Individuals with HIV

By Rene Pretorius

December 13, 2024

The BEe-HIVe Randomized Clinical Trial results are out. The study investigated whether vaccination with a hepatitis B vaccine with a cytosine phosphoguanine adjuvant (HepB-CpG vaccine) improve hepatitis B virus (HBV) seroprotection in people with HIV and nonresponse to prior hepatitis B vaccine?  The results compare the efficacy and safety of different hepatitis B vaccine regimens, particularly the efficacy of the Heplisav-B vaccine for individuals living with HIV.

Hepatitis B Vaccine Efficacy

The Heplisav-B vaccine, known scientifically as HepB-CpG, has proven to be highly effective in inducing protective antibody responses in people living with HIV. In a recent international study, Heplisav-B achieved protective levels of antibodies in up to 99.4% of participants, significantly outperforming the traditional HepB-alum vaccine (Engerix-B), which achieved protection in only 80.6% of subjects.

Comparison with Traditional Vaccines

The study compared the efficacy of the Heplisav-B vaccine with the HepB-alum vaccine and found that both the three-dose and two-dose regimens of Heplisav-B were superior to the three-dose regimen of Engerix-B. The three-dose Heplisav-B regimen resulted in 99.4% seroprotection, while the two-dose regimen yielded 93.1% seroprotection.

Specifics of the BEe-HIVe Trial

The NIH-sponsored BEe-HIVe trial involved 561 participants living with HIV from 40 sites across North and South America, Africa, and Asia. These participants had previously been vaccinated against hepatitis B but lacked protective antibody levels. The trial demonstrated the clear superiority of Heplisav-B over Engerix-B in inducing protective antibody responses.

Safety and Durability

Importantly, the trials did not uncover any new safety issues associated with the Heplisav-B vaccine. Moreover, earlier studies and the current analysis indicate that Heplisav-B induces high and durable antibody responses, crucial for long-term protection against hepatitis B.

High-Dose vs Standard-Dose Regimens

Additional studies have explored the efficacy of high-dose versus standard-dose HBV vaccine regimens for revaccination in patients with HIV. These studies found that high-dose regimens resulted in higher and longer-lasting serological responses compared to standard-dose regimens. For instance, a high-dose regimen of 40 μg recombinant hepatitis B vaccine achieved a 72% serological response rate, compared to just 51% for the standard-dose regimen.

Implications for Clinical Practice

The findings suggest that clinicians will likely prefer using the Heplisav-B vaccine over traditional alum-adjuvant vaccines to boost immunity against hepatitis B in adults with HIV, especially those with little or no existing antibody protection. This is critical, considering the impaired immune response in individuals with HIV, which often limits the effectiveness of traditional vaccines.

In conclusion, the Heplisav-B vaccine, with its cytosine phosphoguanine adjuvant, is significantly more effective in inducing protective antibody responses in people living with HIV compared to traditional vaccines. This positions it as the preferred option for vaccination and revaccination strategies in this vulnerable population.

Reference url

Recent Posts

elderly care costs 2025
      

Elderly Care Costs 2025: Rising Financial Pressures in Dutch Health Services

💡 Are you prepared for the surge in elderly care costs projected for 2025?

A recent report from Zorginstituut Nederland reveals that the financial burden on the Dutch health system is set to rise significantly due to demographic shifts and increased demand for complex care. As policymakers navigate these challenges, the insights address crucial implications for health economics, reimbursement strategies, and sustainable access to care.

Don’t miss out on understanding how these trends could shape the future of healthcare. Dive into the full article for comprehensive insights!

#SyenzaNews #HealthEconomics #HealthcarePolicy #DigitalTransformation

silencing science impact
      

Silencing Science Impact: Political Interference and Global Health Consequences

🔍 Are political interventions threatening the very foundation of scientific integrity?

A recent article from the BMJ highlights alarming shifts within U.S. governance that are undermining scientific autonomy, equity in health research, and public trust. From funding cuts to the suppression of critical fields like climate science, the implications are far-reaching.

Curious about how these changes may affect the future of healthcare and innovative reimbursement? Dive into the full discussion to understand the stakes and potential solutions.

#SyenzaNews #HealthEconomics #HealthcarePolicy

AAP childhood obesity guidelines
     

Caution Advised: Conflicts in AAP Childhood Obesity Guidelines

Are childhood obesity guidelines driving us toward conflict? 🌍 The recent AAP guidelines suggest weight loss medications for children as young as eight, but undisclosed financial ties to drug manufacturers raise serious questions about credibility.

In this article, we dive into the implications of these conflicts and the evidence gaps surrounding pharmaceutical interventions in pediatric care. Transparency and trust are crucial when it comes to the health of our children—let’s explore what needs to change.

Read more to find out how these guidelines could impact families, clinicians, and healthcare policy.

#SyenzaNews #HealthcareInnovation #HealthcarePolicy

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.